IMPORTANCE Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine.
T he passage of the US Food and Drug Administration's Breakthrough Designation Act in 2012 and development of targeted therapeutics for patients with cancer have accelerated access to life-prolonging and, in some cases, curative medications, often based on substantial effect sizes seen in smaller, earlier-phase clinical trials. 1 In 2016, the 21st Century Cures Act recognized the need for "real-world evidence" to further establish the benefit of these agents, understand their optimal use, and inform future trial design. 2 Population-based, research-grade, linked clinicogenomic data sets generated from routine clinical care could significantly accelerate the advancement of clinical practice and the development of novel therapeutics. Most efforts to identify clinicogenomic associations currently rely on clinical trials, 3 single-institution series, 4 or national registries. 5 Multi-institutional efforts, such as the American Association for Cancer Research's Genomics Evidence Neoplasia Information Exchange, have provided valuable insights but favor academic practice settings, whereas 85% of US patients receive oncologic care in the community. 6 Further, these observational data sets often are limited by heterogeneous or absent molecular testing, minimal clinical annotations of therapy and response, and limited or sometimes absent longitudinal updates. The purpose of this study was to evaluate whether a newly developed, continuously updating clinicogenomic databasewhich included patient data collected routinely as part of health care delivery, with clinical data linked with comprehensive genomic profiling (CGP) results-was representative of known features of patients with non-small cell lung cancer (NSCLC), could replicate well-established genomic correlations with clinical outcomes, and would be useful for novel hypothesis generation, in particular related to immunotherapy.
Methods

Regulatory Compliance and Cohort Generation
Approval for this study was obtained from the New England Institutional Review Board prior to study conduct, and the requirement for participant informed consent was waived. De-identification of patient data was performed according to Health Insurance Portability and Accountability Act guidelines and confirmed by an external statistical review process. The cohort was generated by linking the Flatiron Health electronic health records (EHRs) database to the Foundation Medicine database of tumor sequencing results (eFigure 1A in the Supplement). 7 Strictly deidentified "tokens" (hashed patient identifiers derived from, but not including, protected health information) were deterministically generated from each patient's demographic data and overlapped by a third party (Management Science Associates). Deidentified clinical and genomic data were submitted independently to Management Science Associates for linkage using the tokens without accessing personal health information. The linked, deidentified database was transferred for analysis with new deidentified tokens replacing the original tokens, preventing relinking to internal identified data sets (eFigure 1B in the Supplement). While the clinicogenomic database is refreshed every 3 to 6 months, the analyses reported here were based on the data as of January 1, 2018. An NSCLC subcohort was defined by identifying patients who had an International Classification of Diseases (ICD) code for lung cancer within their EHR (ICD-9: 162.x; ICD-10: C34.x or C39.9), who were seen at an oncology practice in the clinical database at least once after January 2011, had medical record-confirmed diagnosis of NSCLC after manual review of the EHR, and had commercial CGP testing on a tumor specimen that a pathologist determined to be NSCLC or cancer of unknown primary. Patients were included if their CGP sample date was no earlier than 1 month prior to clinical diagnosis of NSCLC per medical record review.
Tumor Genotyping and PD-L1 Determination
Targeted DNA sequencing was performed on formalin-fixed, paraffin-embedded tissue using the FoundationOne platform, which includes full exonic coverage of 395 genes and intronic analysis for rearrangements at a depth of 500-1000x in its most current iteration (87.7% of all samples; eTable 1 in the Supplement).
8 Point mutations, amplifications, deletions, duplications, insertions, splice site variants, and rearrangements were categorized as either known pathogenic, likely pathogenic, variants of unknown significance, or germline single-nucleotide polymorphisms. 9 A National Comprehensive Cancer Network (NCCN)-listed driver mutation was defined as a pathogenic alteration in EGFR, ALK, ROS1, MET, BRAF, RET,orERBB2. Tumor mutational burden (TMB), a measure of the number of somatic mutations identified per megabase of DNA sequenced, was calculated for every patient in the cohort. 10 Patients were stratified into TMB-high (TMB-H, ≥20 mutations/Mb) and TMB-low/ intermediate (TMB-L/I, <20 mutations/Mb) based on prior efforts to define TMB cutoffs for response to immunotherapy.
A sample was classified as PD-L1 positive when reported as "positive" in the EHR or when testing by the central laboratory conducting next-generation sequencing revealed 50% or greater staining using either the 22C3 or SP142 PD-L1 antibodies. All other cases were deemed indeterminate or unknown. PD-L1 testing was included in survival and time receiving therapy analyses if reported before or within 30 days of the index start date. If multiple samples matched these criteria, the PD-L1 test temporally closest to the index date was selected.
Clinical Data Extraction
The clinical database contains longitudinal structured and unstructured EHR data from 275 cancer clinics representing more than 2 million actively treated US patients with cancer (approximately 85% from community practices). Structured data were harmonized and normalized to a standard ontology (aligning, where possible, to existing standards such as Logical Observation Identifiers Names and Codes for laboratory test results and North American Association of Central Cancer Registries standards for data elements commonly reported in tumor registries). Additional data points of interest (eg, smoking status, date of advanced disease diagnosis, biomarker status, and dates of disease progression) were extracted from unstructured EHRderived digital documents via manual review by trained medical record abstractors (clinical oncology nurses and tumor registrars, with oncologist oversight) who followed prespecified, standardized policies and procedures. Race/ethnicity, as recorded in the EHR as part of clinical care, was included in this study given previous associations with outcomes in NSCLC.
End Points
The main end points were overall survival (time until death or loss to follow-up), time receiving therapy (duration of exposure to the therapy of interest within the earliest line containing said treatment; for instance, if a patient received erlotinib as part of both the second and fourth lines of therapy, the duration of the second line of therapy would be considered for this analysis), maximal therapeutic response (MTR; maximum response to a given therapy recorded in the EHR), and clinical benefit rate (CBR; the fraction of patients experiencing stable disease, partial response, or complete response). For most analyses, only a single end point was studied based on the end point best described previously. For some analyses with multiple previously described end points, each end point was studied and reported. Overall survival was derived from a recent mortality data set generated by combining multiple data sources and benchmarked against the National Death Index.
12 Specifically, 4 sources of data were combined to develop a death data set of high sensitivity and specificity relative to standard National Death Index data: (1) EHR structured data contained within the clinical database; (2) abstracted data from EHR unstructured documents (eg, end-of-treatment notes or condolence letters); (3) commercial death data purchased from a vendor; and (4) publicly available US mortality data from the Social Security Death Index. Time receiving therapy was derived from structured medication orders and administrations recorded in the EHR, as well as manual medical record review of notes describing therapeutic regimens. The MTR variable was derived from retrospective review of longitudinal physician assessments of radiographic response to a particular therapy as documented in the EHR (using the NSCLC clinical tumor response variable, version 1.0); given that routine clinical practice does not include RECIST measurements, detailed policies and procedures for manual medical record review were defined to capture this variable reproducibly. MTR was classified as complete response, partial response, stable disease, or progressive disease. CBR was defined as the fraction of patients experiencing stable disease, partial response, or complete response.
Statistical Analysis
All patients in the cohort were included in the descriptive statistics, whereas all other analyses, including overall survival, time receiving therapy, and MTR, were restricted to the patients with advanced-stage disease unless otherwise noted. Descriptive statistics included median and range for continuous variables, and percentages and frequencies for categorical variables. 95% CIs around binomial proportions were calculated using either the Wilson score or Clopper-Pearson exact interval. Boxplots show the median and interquartile range (IQR) on the box, with whiskers extending to the furthest data point within 1.5 times the IQR. The log-rank test was used to compare groups. Confidence intervals on median survival time differences were calculated by bootstrapping 500 replicates. Patients were excluded from specific analyses when any relevant data (eg, PD-L1 test results) were missing, which varied based on data required for any given analysis. Missingness for each clinical variable is described in the Table and in general was limited across the variables. In addition, 87.7% of patients were tested on the latest version of the CGP baitset (T7), each of whom had complete information on all 395 genes in the panel; the remaining 12.3% had sequencing performed on baitsets that had most of the same genes. TMB was available for every sequenced case. To account for left truncation, patients were treated as at risk of death only after the later of their sequencing report date and their first visit in the analytic database after January 1, 2011, as both are requirements for inclusion in the cohort. To account for potentially conflicting censor dates across the 2 data sets, records for whom the medical record terminated before their sequencing test was reported were removed from survival analyses. To account for potential immortal time bias, exposure to therapy was treated as a time-varying covariate in relevant analyses. Unless specified, only known or likely pathogenic alterations were considered in analyses.
In comparisons of gene frequencies between groups, the Benjamini-Hochberg method was applied and both uncorrected and corrected P values are reported to account for multiple hypothesis testing. The proportionality of hazards assumption was tested for all Cox model analyses by plotting the Schoenfeld residuals and was not violated unless specifically noted. Multivariable models incorporated age, sex, race/ ethnicity, smoking status, pathology, line of first exposure to anti-programmed cell death protein 1 (PD-1)/PD-L1 therapy, EGFR mutations and ALK fusions, TMB, and PD-L1 status. Statistical tests were 2-sided. P values of less than .05 were considered statistically significant. As numerous associations were explored in these analyses, the conclusions should be considered exploratory and interpreted as demonstrations of feasibility. Analyses were performed on the R software version 3.5.1 (R Foundation for Statistical Computing) and Python software version 3.6.5 (Python Software Foundation).
Results
Clinicogenomic Features and Associations
The entire database included 28 998 patients across 38 tumor types, of which 4064 carried a diagnosis of NSCLC and were included in the cohort (eFigure 1C-D in the Supplement). The Table summarizes the clinical characteristics of the patients included in this analysis. The median age at diagnosis was 66.0 years (IQR, . Slightly more than half of patients were female (51.9%, n = 2109), most were white (79.4%, n = 2816), and most had a history of smoking (79.3%, n = 3183). A total of 77.6% (n = 3153) of the tumors were nonsquamous cell carcinoma, 17.9% (n = 726) were squamous cell carcinoma, and 4.6% (n = 185) not otherwise specified. Most patients had stage III (22.0%, n = 846) or IV (59.9%, n = 2304) disease at the time of initial diagnosis. At the time of this analysis, 86.7% of the patients had advanced disease, defined as stage IIIB/IV disease at diagnosis or recurrent or metastatic disease at any stage. Frequencies of data missingness are also reported in the Table (eg, for 1.3% of patients, smoking history information was unavailable in the health record).
The distribution of mutated genes was similar to previous descriptions from The Cancer Genome Atlas (data freeze 10), with a few notable exceptions (eg, point mutations and insertion/ deletions in EGFR)( Figure 1 and Figure 2 ; eFigure 2A-B in the Supplement). 13 , n = 2859, P < .001) (eFigure 3B-C in the Supplement). A co-mutation plot enabled visualization of sex, smoking status, pathology, stage, mutated genes, and TMB for each patient in the NSCLC cohort (eFigure 4 in the Supplement). Associations between driver alterations and clinical characteristics were consistent with prior reports (eTable 2 in the Supplement). For example, EGFR, ALK, and MET alterations were enriched in nonsquamous pathologies (nonsquamous vs squamous: 91.6% vs 5.9%, P < .001 for EGFR mutant; 93% vs 3.9%, P < .001 for ALK mutant; and 86.4% vs 10%, P = .009 for MET mutant). Patients with EGFR mutations were more often Asian (mutant vs WT: 8.4% vs 2.0%; P < .001), female (62.8% vs 49.6%; P < .001), and never smokers (46.9% vs 14.8%; P < .001). Those with ALK translocations were more often younger (mutant vs WT: 58.0 vs 67.0 years old; P < .001) and never smokers (57.0% vs 19.2%; P < .001). Patients with MET alterations were more often older (mutant vs WT: 71.0 vs 66.0 years old; P < .001). b Race/ethnicity data were collected when recorded in the electronic health record as part of routine clinical care. "Other" included a myriad of terms describing race/ethnicity that were entered into the electronic health records; thus, it cannot be mapped to more specific categories.
c Stage of NSCLC is defined by the American Joint Committee on Cancer staging system and stage data were collected when recorded in the electronic health record as part of routine clinical care.
d Line of therapy is defined as a particular treatment regimen administered within a course of care. For example, a patient who has received 2 lines of therapy will have received 2 treatment regimens.
Prognostic Implications of Clinical and Genomic Features
All subsequent analyses were restricted to the patients in the cohort with advanced disease (n = 3522), unless otherwise noted. The median overall survival from advanced diagnosis across this cohort was 10.3 months (95% CI, 9.7-10.9) with a 5-year survival rate of 3.8% (eFigure 5A in the Supplement). Never smokers (n = 661) had longer overall survival from advanced diagnosis than those with a smoking history (n = 2564) (median overall survival, 15.2 months [95% CI, 12.9-18.4] vs 9.6 months [95% CI, 9.1-10.2]; difference, 5.5 [95% CI, 3.4-8.4]; P < .001), and patients with nonsquamous pathology (n = 2556) had longer overall survival than patients with squamous (n = 558) or not otherwise specified (n = 140) pathologies (median overall survival, 10.7 months [95% CI, 10.1-11.5] vs 9.6 months [95% CI, .3] vs 6.4 months [95% CI, 4.4-8.8], respectively; P < .001) (eFigure 5B-D in the Supplement). TP53 (n = 2090 mutant, n = 1164 WT) and RB1 (n = 241 mutant, n = 3013 WT) mutations were associated with shorter survival from advanced diagnosis (median overall survival, 9.6 months [95% CI, 9. Figure 3A ; eFigure 6A in the Supplement).
Treatment Patterns and Genomic Variables Associated With Response to Targeted Therapy
Most patients with EGFR, ALK, and ROS1 WT tumors were initially treated with a platinum-based chemotherapy regimen, whereas those with an EGFR or ALK alteration most commonly received a targeted anticancer agent (eFigure 7A in the Supplement). Among all patients with an advanced diagnosis who had an NCCN-driver alteration (n = 1260), 48.3% (n = 609) received NCCN-recommended therapy after the advanced diagnosis; 64.3% of patients with EGFR alterations (n = 405 of 630) and 70.1% of patients with ALK rearrangements (n = 75 of 107) received targeted therapies after advanced diagnosis. 
Clinicogenomic database
The Cancer Genome Atlas
The frequency of short variant mutations (alterations that do not include translocations, large deletions, or copy number changes) identified in clinicogenomic database (CGDB) tumors analyzed on the most updated FoundationOne platform (T7 baitset; n = 2774 adenocarcinoma, n = 636 squamous cell carcinoma; eTable 1 in the Supplement) are shown in dark blue and among those in the The Cancer Genome Atlas (TCGA) (n = 567 adenocarcinoma, n = 495 squamous cell carcinoma) are shown in light blue for the 20 most commonly mutated genes. Adenocarcinomas and squamous cell cancers were analyzed separately given the well-established differences in mutational landscape between these tumor types. The genomic distribution and frequency of mutations were similar between the CGDB and TCGA in both adenocarcinoma and squamous cell lung cancers. For example, TP53 was the most commonly mutated gene in both pathologies, EGFR mutations were more common in adenocarcinoma, and CDKN2A mutations were more common in squamous cell histology. The most common second-line agent administered to those previously exposed to a platinum-based treatment was an anti-PD-1/PD-L1 agent (nivolumab, pembrolizumab, atezolizumab, durvalumab, or avelumab), a therapeutic class whose use increased over time during the observation period (eFigure7BintheSupplement). Among patients with a mutation in an NCCN-listed gene with evaluable overall survival, exposure to NCCN-directed targeted therapy treatment (n = 575 received, n = 560 did not receive) was associated with longer overall survival from advanced diagnosis (median overall survival, 18.6 months [95% CI, 15.2-21.7] vs 11.4 months [95% CI, 9.7-12.5]; difference, 7.1 [95% CI, 3.5-10.1]; P < .001) ( Figure 3B ). In particular, among patients with an EGFR alteration, treatment with an EGFR inhibitor (n = 380 received, n = 186 did not receive) was associated with longer overall survival from advanced diagnosis (median overall survival, 21.0 months [95% CI, 17.5-26.4] vs 13.3 months [95% CI, 10.8-14.6]; difference, 7.8 [95% CI, 4.7-13.9]; P < .001) ( Figure 3C ). Additionally, among all patients treated with an EGFR inhibitor, those with an EGFR alteration (n = 405) had a longer time receiving therapy (median time receiving therapy, 10.3 months [95% CI, 8.7-11.5] vs 2.8 months [95% CI, 2.4-3.7]; difference, 7.5 [95% CI, 5.6-8.7]; P < .001) and significantly higher MTR (CBR, 86.1% vs 50.9%; P < .001) compared with patients without an EGFR alteration (n = 148) (eFigure 7C and eTable 3 in the Supplement).
Immunotherapy, TMB, and PD-L1 Status
A total of 1290 patients received anti-PD-1/PD-L1 agents either as monotherapy or as part of a combination regimen. Compared with patients without anti-PD-1/PD-L1 therapy exposure (n = 2774), these patients had similar distributions of mutations and smoking history, with notable exception of significantly lower prevalence of alterations in EGFR (10.8% vs 20.4%; uncorrected and corrected P < .001) or ALK (1.3% vs 3.7%; uncorrected P < .001 and corrected P = .002) (eFigure8A-CintheSupplement).
PD-L1 testing results were available for 1235 patients (11 commercial vendors, including Foundation Medicine). A total of 482 patients had positive or negative results and received anti-PD-1/PD-L1 therapy. Median TMB did not significantly differ in the PD-L1-positive (n = 289) vs -negative (n = 662) groups (median, 6.95 mutations/Mb [IQR, 3.5-14.0] in each group), consistent with prior reports ( Figure 4A ).
14 Bivariable analysis showed no association between PD-L1 status and time receiving therapy or overall survival among patients who received anti-PD- Potential prognostic significance of TMB was assessed by analyzing patients with advanced disease who did not receive anti-PD-1/PD-L1 therapy. TMB-H was not associated with overall survival from advanced diagnosis in this population (TMB-H vs TMB-L/I median overall survival: 9.0 months [95% CI, 7.3-11.1], n = 226 vs 7.9 months [95% CI, 7.2-8.7], n = 1751; difference, 1.1 [95% CI, −0.89 to 2.8]; P = .11) (eFigure 9C in the Supplement). In the anti-PD-1/PD-L1-treated group, TMB-H was associated with significantly longer overall survival from start of treatment (median overall survival, 16.8 months [95% CI, 11.6-24.9], n = 161 vs 8.5 months [95% CI, 7.6-9.7], n = 1116; difference, 8.3 [95% CI, 2.1-15.6]; P < .001) and duration on anti-PD-1/PD-L1 therapy (median time receiving therapy, 7.8 months [95% CI, 5.5-11.1], n = 162 vs 3.3 months [95% CI, 2.8-3.7], n = 1127; difference, 4.5 [95% CI, 2.1-7.9]; P < .001) than TMB-L/I ( Figure 4B ; eFigure 9D in the Supplement). Similarly, the MTR to anti-PD-1/PD-L1 therapy was greater in the TMB-H group (n = 119) than in the TMB-L/I group (n = 789) (CBR, 80.7% vs 56.7%; P < .001) (eFigure 9E in the Supplement). In PD-L1-negative patients, TMB-H was not significantly associated with increased time receiving therapy or overall survival from start of therapy compared with TMB-L/I (median time receiving therapy, 11.3 months [95% CI, 2. 
Gene
To gain insight into the mutational landscape of the NSCLC clinicogenomic database cohort, alterations were identified for all patients tested on the most updated FoundationOne platform (n = 3564; eTable 1 in the Supplement). The alterations were then classified as likely impairing protein function and therefore pathogenic or of unknown significance using predefined algorithms (Methods section). The most commonly mutated gene across the cohort was TP53. n = 219; difference, 4.2 [95% CI, −1.2 to + ϱ], P = .10) (eFigure9F -GintheSupplement). In a multivariable Cox proportional hazard analysis, higher TMB was associated with a significantly lower risk of discontinuing therapy (hazard ratio [HR], 0.78 for every additional 10 mutations/Mb [95% CI, 0.65-0.95]; P = .01), while receipt of anti-PD-1/PD-L1 therapy in second line or later (HR, 1.19 for every additional line after first [95% CI, 1.04-1.36]; P = .01) was associated with increased risk of discontinuing therapy (eTable 4 in the Supplement). PD-L1 status was not significantly associated with risk of discontinuing therapy (HR, 0.82 [95% CI, 0.62-1.12]; P = .21).
Discussion
Exploratory analyses of the NSCLC cohort of a clinicogenomic database generated by linking EHR-derived clinical data with CGP results obtained during routine clinical care from nearly 29 000 patients representing more than 38 tumor types from more than 180 largely community-based oncology practices replicated previously described associations between clinical and genomic characteristics, driver mutations and response to targeted therapy, and TMB and response to immunotherapy. The replication of clinicogenomic correlations previously identified through clinical trials, institutional studies, and academic sequencing efforts help establish the validity and applicability of this method. These findings are consistent with the results from the French Cooperative Thoracic Intergroup study of molecular alterations in advanced NSCLC.
5 Data sets derived from routine clinical practice may provide certain new or validated insights, such as the observation that treatment with an EGFR inhibitor in EGFR mutant disease was associated with prolonged survival, a finding that has been difficult to confirm in clinical trials due to crossover.
This data set further enabled the exploratory study of biomarkers associated with response to immunotherapy. Consistent with recent clinical trial data, TMB was found to be associated with both duration on anti-PD-1/PD-L1 therapy and survival from therapy start in bivariable and multivariable analyses, controlling for clinical and genomic confounders. Extending these findings, including the addition of multifactorial analyses with immune-associated genomic biomarkers, may help define additional and more robust variables associated with response to immunotherapies.
In addition, the use of large-scale clinicogenomic data sets can augment various stages of drug development. For example, a better understanding of the relationship between genomic drivers, patient information, and therapeutic response can inform target identification and focus discovery efforts on specific genomic subtypes, patients, or treatment modalities. Similarly, a deeper understanding of the genomic landscape across patient populations and how these patients respond to standard of care treatments may improve clinical trial design, including, for example, modeling expected performance of unexposed control populations for a novel therapy.
Limitations
This study has several limitations. First, a fundamental limitation of all overall survival analyses conducted using data collected from routine clinical practice is the quality and completeness of the underlying mortality data. While not every deceased patient's date of death was captured, and all biases in the distribution of this missingness were not known, the mortality data included in this clinicogenomic database had been previously validated as having high completeness and accuracy relative to gold-standard data sets.
12
Second, the inclusion requirement of CGP testing results could create a survival bias; to mitigate this bias, left truncation was accounted for in the survival analyses. Third, bias could be introduced in the analysis of therapeutic exposures without randomization. To limit any potential immortal time bias, survival analyses comparing cohorts with differential treatment exposure incorporated therapy exposure as a timevarying covariate. Fourth, the requirement of CGP testing may introduce a selection bias for those with access to, and under the care of, physicians with distinct practice patterns. However, the data set included a broad set of patients including diversity in age, sex, and stage of disease.
Fifth, the time receiving therapy end point may not account for non-progression-related reasons for discontinuing therapy; efforts to integrate additional information (eg, radiology and pathology) may further refine this metric. Sixth, the MTR end point was limited by the physician's interpretation and documentation of the response; however, the ability to ascertain the interpretation of the treating clinician may reflect a clinically meaningful response not captured using other metrics. Seventh, the cohort was largely composed of patients with advanced-stage disease, a population in which CGP was more typically ordered. This needs to be considered when evaluating comparative results with other data sets, as the clinical and genomic landscape may change as the disease progresses. Overall survival of patients from advanced diagnosis (b) Overall survival of patients from advanced diagnosis stratified by age greater or less than 65 years old at advanced diagnosis (c) Overall survival of patients from advanced diagnosis stratified by smoking history (d) Overall survival of patients from advanced diagnosis stratified by pathology
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eFigure 6: Genomic Predictors of Survival and Therapy Response (a) Overall survival from advanced diagnosis of patients stratified by mutation status of RB1 (top) and TP53 (bottom) (b) Overall survival from advanced diagnosis of patients stratified by the presence of an NCCN driver mutation (NCCN drivers include EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2)
Overall survival from advanced diagnosis of patients stratified by presence of mutation in specified gene Distribution of median tumor mutational burden in anti-PD-1/PD-L1 treated patients stratified by presence of genetic mutation for all patients (green), those with a history of smoking (red), and those without a history of smoking (orange) * For purposes of uniformity, only data from patients for whom tumor sequencing was done on the most updated FoundationOne platform (see eTable 1) are presented here. The heavy horizontal line is the median, the top and bottom edges of the box correspond to the upper and lower 25% respectively, the error bar extends to 1.5 times the interquartile range, the open circles are outliers. 
